I[ntroduction]{.smallcaps} {#sec1-1}
==========================

Sepsis is a complex pathology that arises from deregulated host inflammatory responses to systemic bacterial infection\[[@ref1]\] and remains one of the leading causes of death in Intensive Care Units (ICUs).\[[@ref2][@ref3][@ref4]\] Sepsis is characterized by an intravascular activation of the host\'s inflammatory pathways by which potent inflammatory mediators are released into the circulation\[[@ref5]\] and is associated with septic shock, sequential multiple organ failure, and high-mortality rate. Typically, 50% of all sepsis cases start as an infection in the lungs.\[[@ref6]\] Acute lung injury, especially adult respiratory distress syndrome, is a severe, life-threatening medical condition characterized by widespread inflammation in the lungs, with a high mortality of about 30%.\[[@ref7]\]

It is common in a clinical setting that combined isoflurane with oxygen is applied for anesthesia of operation patients. The previous studies have reported that both hyperoxia\[[@ref8][@ref9][@ref10][@ref11]\] and anesthetic dose isoflurane\[[@ref12][@ref13][@ref14]\] have significant protective effects on complex inflammation-mediated conditions including sepsis in various animal models of inflammation, and their application to the patients with critical diseases is limited because the use of anesthetic dose isoflurane in critically ill patients may have serious adverse consequences.\[[@ref15][@ref16][@ref17]\] A large number of trials have demonstrated the safety of long-time lower doses of isoflurane for ICU sedation,\[[@ref18][@ref19]\] and long-term hyperoxia treatment can induce oxygen toxicity associated with the overproduction of reactive oxygen species (ROS).\[[@ref20][@ref21][@ref22][@ref23]\] Here, we demonstrated that combined administration of a low-dose isoflurane (0.5 minimum alveolar concentration \[MAC\]) with 60% oxygen reduced inflammatory responses to sepsis in animals and human peripheral blood mononuclear cells (PBMCs) and increased the 7-day survival rate of animals with experimental sepsis.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Animals {#sec2-1}
-------

We used male C57BL/6 and ICR/Km (Institute of Cancer Research, National Institutes of Health, USA/Kunming Institute of Zoology, China) mice (specific pathogen-free, 20--25 g) and Sprague-Dawley (SD) rats (specific pathogen-free, 250--300 g) for these studies. One week before experimental manipulation, the animals were allowed to acclimatize to the experimental housing facilities. Animals were maintained in a constant 12-h light--dark cycle at 20°C--22°C with standard food and water available *ad libitum*. We performed all experiments according to the National Institutes of Health guidelines. The experimental protocols were approved by the Institutional Animal Care and Use Committee of the Fourth Military Medical University.

Patients {#sec2-2}
--------

Between July and September 2014, we collected blood samples from patients with or without sepsis who were admitted to Xijing Hospital, Fourth Military Medical University (Xi'an, China), as part of a study of the effects of oxygen and oxygen plus volatile anesthetics on experimental sepsis (ClinicalTrials.gov NCT02185118). Information of these patients is shown in Supplementary Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. We obtained written informed consent from patients' proxy decision-makers before the study inclusion. After the individuals regained decision-making capacity, they were told about their participation, and re-consent was obtained according to the institutional policies. Inclusion and exclusion criteria were determined according to the diagnostic criteria for sepsis based on the literature.\[[@ref24]\] The Institutional Review Board of Xijing Hospital, Fourth Military Medical University, approved all of the human protocols.

###### 

Basic information and signs of patients with sepsis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                   Case 1                                                           Case 2                        Case 3
  --------------------------------- ---------------------------------------------------------------- ----------------------------- --------------------------------
  Hospital number                   B85313                                                           B86324                        B86505

  Gender                            Female                                                           Male                          Female

  Age (years)                       44                                                               77                            49

  Temperature (°C)                  37                                                               36                            36.5

  Heart rate (beats/min)            112                                                              72                            104

  Respiratory rate (beats/min)      26                                                               15                            26

  Mental status                     Sober                                                            Sober                         Sober

  Plasma glucose (mmol/L)           5.60                                                             5.61                          5.78

  Leukocyte (×10^9^/mm^3^)          11.92                                                            5.62                          7.67

  CRP (mg/L)                        20.9                                                             --                            32.5

  PCT (ng/ml)                       --                                                               --                            --

  Platelet (×10^9^/mm^3^)           327                                                              155                           227

  Blood pressure (mmHg)             94/49                                                            134/92                        149/79

  Creatinine level (µmol/L)         141                                                              116                           --

  Coagulation (INR)                 1.05                                                             1.47                          1.15

  Bowel sounds                      Normal                                                           Normal                        Normal

  Plasma total bilirubin (µmol/L)   --                                                               26.9                          11.2

  PaO~2~ (mmHg)                     47.2                                                             63.7                          32.6

  PaCO~2~ (mmHg)                    40.3                                                             36.5                          79.2

  BE (mmol/L)                       5                                                                --1                           12.7

  Lactate (mmol/L)                  1.17                                                             1.19                          1.22

  Diagnosis                         Severe pneumonia\                                                Type 1 respiratory failure\   Bronchiectasis with infection\
                                    Respiratory failure\                                             Pulmonary infection\          Type 2 respiratory failure\
                                    Chronic obstructive pulmonary disease with acute exacerbation\   Stage 3 hypertension\         NYHA functional Class III\
                                    Electrolyte imbalance\                                           Renal dysfunction\            Hypoalbuminemia
                                    Acute renal failure                                              Abnormal liver function       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

1 mmHg = 0.133 kPa. CRP: C-reactive protein; PCT: Procalcitonin; INR: International normalized ratio; PaCO~2~: Arterial blood partial pressure of carbon dioxide; PaO~2~: Arterial partial pressure of oxygen; BE: Base excess; NYHA: New York Heart Association.

###### 

Basic information of patients without sepsis

  Case   Sampling date     Gender   Age (years)   Hospitalization number   Diagnosis
  ------ ----------------- -------- ------------- ------------------------ ----------------------------------------------------------------------
  1      July 31, 2014     Male     41            B88233                   Thoracic 12 spinal nerve sheath tumors
  2      July 31, 2014     Female   69            B89937                   Left knee degenerative joint disease; left knee flexion contracture
  3      August 4, 2014    Female   51            B91431                   Left knee degenerative joint disease
  4      August 5, 2014    Female   65            B86689                   Lumbar disc herniation, type 2 diabetes; left leg varicose veins
  5      August 7, 2014    Female   70            B92047                   Double knee degenerative joint disease; Stage 2 hypertension
  6      August 8, 2014    Female   40            B92305                   Bilateral femoral head necrosis; hypertension, nephritis
  7      August 11, 2014   Male     43            B93003                   Lumbar disc herniation
  8      August 11, 2014   Female   63            B91859                   Lumbar spinal stenosis, lumbar disc herniation, Stage 1 hypertension

Cell culture {#sec2-3}
------------

RAW264.7 cell lines were obtained from the Department of Microbiology, School of Basic Medicine, The Fourth Military Medical University, and maintained in Dulbecco\'s modified Eagle\'s medium (Gibco, New York, USA) supplemented with 10% (volume/volume) heat-inactivated fetal calf serum and penicillin and streptomycin.

Human PBMCs were isolated from heparinized venous blood under endotoxin-free conditions through Ficoll-Hypaque density gradient centrifugation (Pharmacia Fine Chemicals, Piscataway, NJ, USA). The purity of CD14^+^ monocytes \[[Figure 1](#F1){ref-type="fig"}\] was always more than 90% as assessed by immunofluorescence staining and counting.\[[@ref25][@ref26]\]

![Identification of CD14^+^ monocytes in human peripheral blood mononuclear cells. Blood was collected from nonseptic patients and anticoagulated with heparin. PBMCs were separated by a Ficoll-Hypaque density gradient centrifugation, added to plastic flasks, and incubated for 6 h at 37°C. Adherent cells were obtained by washing the flasks for three times with Hank\'s solution and subjected to fluorescence staining to detect CD14 using Alexa-F488-conjugated mouse anti-human CD14 antibody. The purity of CD14^+^ monocytes in human PBMCs was \>90%. Fluorescence images of cells were captured using confocal laser scanning microscopy (original magnification ×90). PBMCs: Peripheral blood mononuclear cell cells; DAPI: 4',6-diamidino-2-phenylindole.](CMJ-130-840-g001){#F1}

Sepsis models {#sec2-4}
-------------

For cecal ligation and puncture (CLP)-induced sepsis, animals were anesthetized with 10% chloral hydrate (3 ml/kg). Briefly, the lower quadrant of the abdomen was disinfected, and a longitudinal skin midline incision was made to expose the cecum. For the induction of mid-grade sepsis (survival rate about 40%), the cecum was ligated half the distance between the distal pole and base of the cecum. High-grade sepsis (100% lethality) comprised ligation of 75% of the cecum. We punctured the cecum ("through-and-through") from the mesenteric toward the antimesenteric direction with a 21-gauge needle, and animals in the sham groups underwent surgery without the CLP procedure. Finally, the abdominal incision was closed in two layers by applying simple interrupted sutures. After surgery, the mice were resuscitated in a warm cage.

Lipopolysaccharide (LPS)-induced sepsis was induced by an intraperitoneal injection of LPS (50 mg/kg for ICR/Km mice and 30 mg/kg for C57BL/6 mice) (Sigma Chemical, St. Louis, MO, USA), with normal saline (NS) as control. Induction of an *in vitro* sepsis was performed on RAW264.7 cell lines with exposure to LPS. A clinical *in vitro* sepsis was induced in human PBMCs by LPS or plasma from septic patients.

Zymosan-induced sterile sepsis was induced by intraperitoneal injection of zymosan (Sigma Chemical Co., St. Louis, MO, USA) at 1 g/kg as was described previously;\[[@ref9]\] sham group was injected with NS.

Treatment with oxygen or isoflurane in oxygen {#sec2-5}
---------------------------------------------

Animals were placed in a sealed plexiglass chamber with an inflow and an outflow. Oxygen and isoflurane (Lunan Pharmaceutical Co., Ltd., Shandong, China) were delivered to the chamber through a tube, and carbon dioxide was removed from the chamber gases with Baralyme. The concentration of oxygen and isoflurane in the outflow hose of the chamber was continuously monitored with a gas analyzer (Bruel and Kjaer, Naerum, Denmark). The concentration of oxygen or isoflurane was maintained at the predetermined level during the treatment. The temperature of the room and the chamber was maintained at 20°C--22°C. The treatment time was in accordance with the previous study.\[[@ref13]\]

The cells were transferred to a sealed hypoxia modular incubator chamber (MIC-101, Billups-Rothenberg, San Diego, California, USA) containing a mixture of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen at 37°C, or normal culture conditions (control) for 2 h, while the chamber was continuously monitored with a gas analyzer (Bruel and Kjaer, Naerum, Denmark).

Histological analysis {#sec2-6}
---------------------

Twenty-four hours after CLP, animals were anesthetized, and the lungs were collected for histological observation with a microscope (Olympus, Tokyo, Japan). The histological slides were read in a blinded manner and assessed by two experienced pathologists.

Arterial blood gas analysis {#sec2-7}
---------------------------

Arterial blood samples were collected from the carotid artery (mice) or femoral artery (rats). The arterial blood gas analysis was performed in all groups using a GEM Premier 3000 gas analyzer (Instrumentation Laboratory, Milan, Italy).

Lung wet to dry weight ratio {#sec2-8}
----------------------------

To quantify the magnitude of the pulmonary edema, we evaluated the lung wet to dry (W/D) weight ratio. The harvested wet lung was weighed. It was then placed in an oven for 24 h at 80°C and re-weighed when it was dried. The lung W/D weight ratio was recorded.

Cell number count and protein assay of the bronchoalveolar lavage fluid {#sec2-9}
-----------------------------------------------------------------------

Bronchoalveolar lavage fluid (BALF) was obtained by cannulating the trachea with a 20-gauge catheter in mice and a 16-gauge catheter in rats. Animals were anesthetized, and the trachea and lung were exposed by thoracotomy. Phosphate-buffered saline (PBS) (pH 7.4) was instilled with a syringe and allowed to stay in the lung for 30 s, which was repeated three times using the same solution. Lavage samples were centrifuged (12,000 ×*g* for 10 min, 4°C). The supernatant was stored at −80°C. The cell pellet was diluted in PBS, and the total cell number was counted with a hemocytometer after staining with trypan blue (Beyotime Biotechnology, Shanghai, China). Neutrophils were counted in cytocentrifuge preparations (Cytospin 3; Shandon Scientific, Cheshire, UK) stained with Diff-Quik stain (Baxter Diagnostics, McGaw Park, IL, USA). Total protein was measured in the cell-free supernatant using the bicinchoninic acid (BCA) method. Bovine serum albumin was used as a standard.\[[@ref27]\]

Assay of serum biochemical parameters {#sec2-10}
-------------------------------------

At the predetermined time points, animals were anesthetized, and blood samples were collected by cardiac puncture for determining serum levels of alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine using a biochemistry autoanalyzer (Hitachi Autoanalyzer 7150; Hitachi, Tokyo, Japan). In addition, serum lactic dehydrogenase was determined spectrophotometrically using a commercially available kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Measurement of lung myeloperoxidase activity {#sec2-11}
--------------------------------------------

The activity of myeloperoxidase (MPO), an indicator of neutrophil infiltration in lung tissue, was detected in homogenized lung supernatants and measured as previously reported\[[@ref28]\] using commercial kits purchased from Cayman Chemical Company (Ann Arbor, MI, USA).

Microvascular albumin leakage in the lung {#sec2-12}
-----------------------------------------

Evans blue (EB) (MP Biomedicals, Shanghai, China) (2%, 4 ml/kg) was injected into the tail vein 2 h before CLP. At 24 h after CLP, lung tissue was homogenized in ice-cold PBS, incubated with formamide at 60°C for 16 h, and centrifuged at 7000 ×*g* for 25 min. The absorbance (*A*~620~) of the supernatant was determined, and the tissue EB content was calculated.\[[@ref29]\]

Assay of inflammatory cytokines {#sec2-13}
-------------------------------

The levels of high-mobility group protein-1 (HMGB1), interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) in cell culture supernatant or serum or plasma or intraperitoneal lavage fluid were detected using specific mouse or human enzyme-linked immunosorbent assay kits (R&D Systems Inc., Minneapolis, Minnesota, USA) with a microplate reader (Denley Dragon, Wellscan MK3, Thermo, Finland). All of the standards and samples were run in triplicate.

Western blot analysis {#sec2-14}
---------------------

The protein from RAW264.7 cell samples was directly extracted based on the manufacturer\'s standard protocols (Beyotime Biotechnology). The cytoplasmic and nuclear protein fractions were extracted using Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime Biotechnology) according to the manufacturer\'s protocol. Cytoplasmic/nuclear protein extracts or whole protein extracts were used for Western blot analysis. The primary rabbit antibodies for nuclear factor kappa B (NF-κB) p65 subunit (p65), phosphorylated NF-κB p65 (p-p65), phosphorylated inhibitor of kappa B alpha (p-IκBβ), and phosphorylated IκB kinase-β/β (p-IKKβ/β) (Cell Signaling Technology, Boston, USA) proteins were used for the detection of p65, p-p65, p-IκBβ, and p-IKKβ/β protein expression. Moreover, the primary rabbit antibodies for proliferating cell nuclear antigen (PCNA), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), IKKβ, IKKβ, IκBβ proteins (Cell Signaling Technology) were used for the detection of PCNA, GAPDH, IKKβ, IKKβ, and IκBβ proteins, which were used as the control. Immunostained proteins were detected by electrochemiluminescence (CWBio Co., Ltd., Beijing, China).

Immunofluorescence staining {#sec2-15}
---------------------------

For the immunofluorescence assays, RAW264.7 cells or freshly isolated PBMCs were seeded on coverslips in 24-well plates and cultured. Immunofluorescence staining of the cells was performed using the NF-κB p65 nuclear translocation kit (Beyotime Biotechnology) manufacturer\'s instruments. The 4',6-diamidino-2-phenylindole staining was used for counterstaining of the nucleus. Fluorescent images of coverslips were obtained by confocal microscopy (Olympus, Tokyo, Japan).

Statistical analysis {#sec2-16}
--------------------

The measurement data are expressed as mean ± standard error (SE). Intergroup differences in the levels of biochemical parameters and inflammatory cytokines were tested by one-way analysis of variance (ANOVA), followed by Dunnett\'s *t*-test for multiple comparisons. Survival studies were analyzed using the log-rank test. The survival rates are expressed as a percentage. The intergroup differences of histopathologic scores were tested by Kruskal--Wallis *H* method, followed by Nemenyi test for multiple comparisons. The statistical analysis was performed with SPSS 20.0 software (SPSS Inc., Chicago, IL, USA). A *P* \< 0.05 was considered statistically significant.

R[esults]{.smallcaps} {#sec1-3}
=====================

Combined administration of 0.5 minimum alveolar concentration isoflurane with 60% oxygen protected against lung injury and sepsis induced by cecal ligation and puncture {#sec2-17}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In CLP-challenged rats with moderate mortality, the 7-day survival rate was markedly decreased to about 40%, and a significant improvement in the 7-day survival rate was observed only in those treated with inhalation of 100% oxygen (75% vs. 40%, *P* \< 0.05) or 0.5 MAC isoflurane in 60% oxygen (80% vs. 40%, *P* \< 0.05) \[[Figure 2a](#F2){ref-type="fig"}\]. Inhalation of 40% oxygen, 60% oxygen, 80% oxygen or 0.5 MAC isoflurane in air, 0.5 MAC isoflurane in 40% oxygen, 0.5 MAC isoflurane in 80% oxygen, and 0.5 MAC isoflurane in 100% oxygen did not have similar protective effects. We also observed that inhalation of 100% oxygen (30% vs. 0%, *P* \< 0.05) or 0.5 MAC isoflurane in 60% oxygen (35% vs. 0%, *P* \< 0.05) improved the 7-day survival rate of rats with a higher mortality induced by CLP \[[Figure 2b](#F2){ref-type="fig"}\].

![Inhalation of 0.5 minimum alveolar concentration isoflurane in 60% oxygen protected against sepsis-induced lethality. Sepsis was induced by CLP or intraperitoneal injection of LPS, zymosan. Various concentrations of oxygen or 0.5 MAC isoflurane in various concentrations of oxygen was inhaled for 1 h at 1 and 6 h after the challenge, respectively. The survival rate was observed for 7 days. The values are expressed as the survival percentage (*n* = 20 for each group). (a) SD rats with CLP-induced moderate sepsis. (b) SD rats with CLP-induced severe sepsis. (c) C57BL/6 mice with LPS-induced sepsis. (d) ICR/Km mice with zymosan-induced sterile sepsis. \**P* \< 0.05 versus NS/Sham+Air group; †*P* \< 0.05 versus ZY/LPS/CLP+Air group, respectively. CLP: Cecal ligation and puncture; LPS: Lipopolysaccharide; MAC: Minimum alveolar concentration; NS: Normal saline; SD: Sprague-Dawley; ISO: Isoflurane; Oxy: Oxygen; ZY: Zymosan.](CMJ-130-840-g002){#F2}

We further observed similar histological changes in lungs from the two animal models \[Figure [3a](#F3){ref-type="fig"} and [3b](#F3){ref-type="fig"}\]. In sham-operated animals, uniform and small alveoli were seen, while alveolar collapse, interstitial edema, congestion, alveolar wall thickening, consolidation involving half of the lung, and heterogeneous alveolar size were observed in animals from the CLP+Air group. Treatment with 100% oxygen or 0.5 MAC isoflurane in 60% oxygen resulted in improvement of the CLP-induced lung impairments. In addition, lung W/D weight ratio (8.48 vs. 5.21, *P* \< 0.05), lung MPO activity (410.4 vs. 72.8 U/100 mg, *P* \< 0.05), lung microvascular EB leak (1.71 vs. 0.88 μg/g, *P* \< 0.05), and BALF protein (1.15 vs. 0.44 mg/ml, *P* \< 0.05) as well as arterial partial pressure of carbon dioxide (52.0 vs. 37.0 mmHg, *P* \< 0.05; 1 mmHg = 0.133 kPa) and arterial blood lactate (4.53 vs. 2.48 mmol/L, *P* \< 0.05) were significantly increased at 24 h after CLP. The pH value (7.23 vs. 7.42, *P* \< 0.05) and arterial partial pressure of oxygen (81.9 vs. 98.3 mmHg, *P* \< 0.05) were significantly decreased at 24 h after CLP. Treatment of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen significantly improved these impairments in SD rats with the CLP challenge \[Figure [3c](#F3){ref-type="fig"}-[3j](#F3){ref-type="fig"}\].

![Inhalation of 0.5 minimum alveolar concentration isoflurane in 60% oxygen reduced cecal ligation and puncture-induced lung injury. CLP-induced sepsis was performed on ICR/Km mice or SD rats. Treatment was conducted by inhalation of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 1 h at 1 and 6 h after CLP, respectively. Lungs were harvested 24 h after CLP for histological observation under optical microscopy (original magnification ×40). Photomicrographs are representative of data obtained from lung sections derived from six animals. (a) Histological assessment of lungs in rats. (b) Histological assessment of lungs in ICR/Km mice. Parameters reflecting lung injury were also determined 24 h after CLP. Data are expressed as the mean ± standard error (*n* = 6 in each group). (c) Lung wet to dry weight ratio. (d) Protein production in the BALF. (e) Lung MPO activity. (f) Lung microvascular albumin leak. (g) Arterial pH value. (h) Arterial partial pressure of oxygen (PaO~2~). (i) Arterial partial pressure of carbon dioxide (PaCO~2~). (j) Lactate in arterial blood. \**P* \< 0.05 versus Sham+Air group; †*P* \< 0.05 versus CLP+Air group. CLP: Cecal ligation and puncture; SD: Sprague-Dawley; MAC: Minimum alveolar concentration; BALF: Bronchoalveolar lavage fluid; MPO: Myeloperoxidase; ISO: Isoflurane; Oxy: Oxygen.](CMJ-130-840-g003){#F3}

The above results imply that combined administration of 0.5 MAC isoflurane with 60% oxygen is the best combination of oxygen and isoflurane for protecting against CLP-induced sepsis.

Combined administration of 0.5 minimum alveolar concentration isoflurane with 60% oxygen protected against lethality in mouse models of sepsis induced by intraperitoneal injection of lipopolysaccharide or zymosan {#sec2-18}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In C57BL/6 mice, intraperitoneal injection of LPS resulted in a marked decrease of the 7-day survival rate to 15%, which was improved significantly by inhalation of 60% oxygen (50.0% vs. 15.0%, *P* \< 0.05), 80% oxygen (49.1% vs. 15.0%, *P* \< 0.05), 100% oxygen (64.0% vs. 15.0%, *P* \< 0.05) or 0.5 MAC isoflurane in 60% oxygen (74.4% vs. 15.0%, *P* \< 0.05), 0.5 MAC isoflurane in 80% oxygen (54.2% vs. 15.0%, *P* \< 0.05) \[[Figure 2c](#F2){ref-type="fig"}\]. In zymosan-challenged ICR/Km mice, the 0.5 MAC isoflurane in 60% oxygen demonstrated the most effective combination of oxygen and isoflurane for improving the 7-day survival of animals (75.0% vs. 30.0%, *P* \< 0.05) \[[Figure 2d](#F2){ref-type="fig"}\]. We also observed that the 0.5 MAC isoflurane in 60% oxygen significantly attenuated lung inflammation and lung injury in zymosan-challenged animals \[Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}\]. These findings revealed that combined administration of 0.5 MAC isoflurane with 60% oxygen is the best combination of oxygen and isoflurane for protecting against sepsis induced by LPS or zymosan. Furthermore, 0.5 MAC isoflurane in 60% oxygen protected heart, liver, and kidney function in animals with experimental sepsis \[Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}\].

![Inhalation of 0.5 minimum alveolar concentration isoflurane in 60% oxygen protected mice against zymosan-induced lung injury 24 h after zymosan injection. Treatment was performed in ICR/Km mice by inhalation of 100% oxygen, 60% oxygen, 0.5 MAC isoflurane, or 0.5 MAC isoflurane in 60% oxygen for 1 h at 1 and 6 h after zymosan/NS injection, respectively. (a) Lung wet to dry weight ratio. (b) Protein production in BALF. (c) Whole cell numbers in BALF. (d) Neutrophil numbers in BALF. (e) Lung MPO activity. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus NS+Air group; †*P* \< 0.05 versus ZY+Air group. MAC: Minimum alveolar concentration; BALF: Bronchoalveolar lavage fluid; MPO: Myeloperoxidase; ISO: Isoflurane; NS: Normal saline; Oxy: Oxygen; ZY: Zymosan.](CMJ-130-840-g004){#F4}

![Inhalation of 0.5 minimum alveolar concentration isoflurane in 60% oxygen improved tissue oxygenation in zymosan-challenged mice. Treatment was performed in ICR/Km mice by inhalation of 100% oxygen, 60% oxygen, 0.5 MAC isoflurane, or 0.5 MAC isoflurane in 60% oxygen for 1 h at 1 and 6 h after zymosan/NS injection, respectively. Arterial blood gas analysis was conducted 24 h after zymosan/NS injection. (a) Arterial pH value. (b) Arterial partial pressure of oxygen (PaO~2~). (c) Arterial partial pressure of carbon dioxide (PaCO~2~). (d) Oxygenation indices (PaO~2~/FiO~2~). (e) Lactate in arterial blood. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus NS+Air group; †*P* \< 0.05 versus ZY+Air group. MAC: Minimum alveolar concentration; NS: Normal saline; FiO~2~: Fraction of inspired oxygen; ISO: Isoflurane; Oxy: Oxygen; ZY: Zymosan.](CMJ-130-840-g005){#F5}

![Assessment of organ function in cecal ligation and puncture-challenged rats with or without treatment of 0.5 minimum alveolar concentration isoflurane in 60% oxygen. Treatment was performed in SD rats by inhalation of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 1 h at 1 and 6 h after CLP, respectively. Parameters for the assessment of heart, lung, liver, and kidney functions were examined 24 h after CLP. (a) Serum ALT levels. (b) Serum AST levels. (c) Serum Cr levels. (d) Serum BUN levels. (e) Serum cTnI levels. (f) Oxygenation parameters. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus Sham+Air group; †*P* \< 0.05 versus CLP+Air group. 1 mmHg = 0.133 kPa. SD: Sprague-Dawley; MAC: Minimum alveolar concentration; CLP: Cecal ligation and puncture; FiO~2~: Fraction of inspired oxygen; ISO: Isoflurane; Oxy: Oxygen; PaO~2~: Arterial partial pressure of oxygen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; BUN: Blood urea nitrogen; cTnI: Cardiac troponin I.](CMJ-130-840-g006){#F6}

![Serum levels of biochemical parameters in zymosan-challenged mice with or without treatment with 0.5 minimum alveolar concentration isoflurane in 60% oxygen. ICR/Km mice were treated with 100% oxygen, 60% oxygen, 0.5 MAC isoflurane, or 0.5 MAC isoflurane in 60% oxygen for 1 h at 1 and 6 h after LPS/NS injection, respectively. Serum levels of biochemical parameters were examined 24 h after zymosan/NS injection. (a) Serum ALT levels. (b) Serum AST levels. (c) Serum Cr levels. (d) Serum BUN levels. (e) Serum LDH levels. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus NS+Air group; †*P* \< 0.05 versus ZY+Air group. MAC: Minimum alveolar concentration; LPS: Lipopolysaccharide; NS: Normal saline; ISO: Isoflurane; Oxy: Oxygen; ZY: Zymosan; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; BUN: Blood urea nitrogen; LDH: Lactic dehydrogenase.](CMJ-130-840-g007){#F7}

The 0.5 minimum alveolar concentration isoflurane in 60% oxygen inhibited peritonitis and systemic inflammation after cecal ligation and puncture {#sec2-19}
-------------------------------------------------------------------------------------------------------------------------------------------------

We determined changes of proinflammatory cytokines TNF-α, IL-1β, IL-6, and HMGB1 in serum or peritoneal lavage fluids 24 h after CLP in rats. CLP induced increases in TNF-α (450.7 vs. 116.7 pg/ml, 229.7 vs. 90.8 pg/ml, all *P* \< 0.05), IL-1β (96.7 vs. 38.5 pg/ml, 20.6 vs. 12.0 pg/ml, all *P* \< 0.05), IL-6 (722.5 vs. 290.4 pg/ml, 116.1 vs. 34.5 pg/ml, all *P* \< 0.05), and HMGB1 levels (985.4 vs. 364.7 ng/ml, 449.3 vs. 215.0 ng/ml, all *P* \< 0.05) in serum and peritoneal lavage fluids, respectively \[[Figure 8](#F8){ref-type="fig"}\]. Both treatments with 100% oxygen and 0.5 MAC isoflurane in 60% oxygen significantly reduced the levels of these cytokines in serum and peritoneal lavage fluid in CLP-challenged animals; for 0.5 MAC isoflurane in 60% oxygen treatment, TNF-α (302.7 vs. 450.7 pg/ml, 149.3 vs. 229.7 pg/ml, all *P* \< 0.05), IL-1β (51.7 vs. 96.7 pg/ml, 12.5 vs. 20.6 pg/ml, all *P* \< 0.05), IL-6 (390.4 vs. 722.5 pg/ml, 86.1 vs. 116.1 pg/ml, all *P* \< 0.05), and HMGB1 levels (592.2 vs. 985.4 ng/ml, 323.7 vs. 449.3 ng/ml, all *P* \< 0.05) in serum and peritoneal lavage fluids were significantly inhibited, respectively. These results suggested that 0.5 MAC isoflurane in 60% oxygen inhibited peritonitis and systemic inflammation induced by CLP.

![Treatment with 0.5 minimum alveolar concentration isoflurane in 60% oxygen attenuated increases of pro-inflammatory cytokines in serum or peritoneal lavage fluid in cecal ligation and puncture challenged rats. Treatment was performed in SD rats by inhalation of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 1 h at 1 and 6 h after CLP, respectively. The levels of inflammatory factors in serum and peritoneal lavage fluid were examined 24 h after CLP. (a) IL-1β in serum. (b) IL-6 in serum. (c) TNF-α in serum. (d) HMGB1 in serum. (e) IL-1β in peritoneal lavage fluid. (f) IL-6 in peritoneal lavage fluid. (g) TNF-α in peritoneal lavage fluid. (h) HMGB1 in peritoneal lavage fluid. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus Sham+Air group; †*P* \< 0.05 versus CLP+Air group. SD: Sprague-Dawley; MAC: Minimum alveolar concentration; CLP: Cecal ligation and puncture; ISO: Isoflurane; Oxy: Oxygen; IL-1β: Interleukin-1β; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha; HMGB1: High-mobility group box 1.](CMJ-130-840-g008){#F8}

Nuclear factor kappa B signaling pathway participated in the protective action against sepsis by 0.5 minimum alveolar concentration isoflurane in 60% oxygen in RAW264.7 cells {#sec2-20}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

An *in vitro* sepsis was induced in RAW264.7 macrophages by 100 ng/ml LPS for at least 2 h based on our preliminary results as shown in [Figure 9](#F9){ref-type="fig"}. Cells were treated by exposure to 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 2 h initiated either simultaneously or at 1 h after the addition of LPS. A significant increase in TNF-α in the cell culture supernatant was observed at least 2 h after LPS stimulation (TNF-α, 195.7 vs. 65.4 pg/ml, 294.5 vs. 121.2 pg/ml, all *P* \< 0.05), which was inhibited by 100% oxygen (TNF-α, 96.5 vs. 195.7 pg/ml, 155.1 vs. 294.5 pg/ml, all *P* \< 0.05) or 0.5 MAC isoflurane in 60% oxygen (TNF-α, 89.5 vs. 195.7 pg/ml, 134.1 vs. 294.5 pg/ml, all *P* \< 0.05) started simultaneously or at 1 h after the addition of LPS. We also found that LPS stimulation induced a significant increase in nuclear NF-κB p65 subunit expression, which was partly reversed by treatment with 100% oxygen or 0.5 MAC isoflurane in 60% oxygen. LPS stimulation led to nuclear translocation of NF-κB p65 subunit, which was blocked by 100% oxygen or 0.5 MAC isoflurane in 60% oxygen. We further detected changes of p-IKKβ/β, p-IκBβ, and p-p65 protein expression in LPS-stimulated RAW264.7 cells with or without treatment of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen. LPS stimulation induced higher expression levels of p-IKKβ/β, p-IκBβ, p-p65 proteins at cellular levels, which were inhibited by treatment of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen. The above results indicated that 0.5 MAC isoflurane in 60% oxygen reduces the inflammatory responses in RAW264.7 cells by inhibiting activation of NF-κB signaling pathway \[[Figure 10](#F10){ref-type="fig"}\].

![Changes in tumor necrosis factor-alpha concentrations of cell culture supernatant from lipopolysaccharide stimulated RAW264.7 cells with or without treatment with 100% oxygen or 0.5 minimum alveolar concentration isoflurane in 60% oxygen. TNF-α concentration in the culture supernatant was detected using an enzyme-linked immunosorbent assay kit. (a) Dose-dependent effects of LPS stimulation for 24 h on TNF-α concentrations. TNF-α level was increased significantly after the stimulation with 100 ng/ml and 1000 ng/ml LPS. (b) Time-dependent effects of 100 ng/ml LPS on TNF-α concentrations. TNF-α level was increased significantly at least 2 h by 100 ng/ml LPS. (c) Treatment with 100% oxygen or 0.5 MAC isoflurane in 60% oxygen significantly inhibited LPS-induced increases of TNF-α concentrations in cell culture supernatants. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus vehicle group; †*P* \< 0.05 versus LPS group. TNF-α: Tumor necrosis factor-alpha; LPS: Lipopolysaccharide; MAC: Minimum alveolar concentration; ISO: Isoflurane; Oxy: Oxygen.](CMJ-130-840-g009){#F9}

![Treatment with 0.5 minimum alveolar concentration isoflurane in 60% oxygen protected against lipopolysaccharide induced *in vitro* sepsis through inhibition to activation of nuclear factor kappa B pathway. An *in vitro* sepsis was induced in the RAW264.7 macrophage cell line through incubation with 100 ng/ml LPS for at least 2 h. Cells were treated with 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 2 h beginning 1 h after LPS stimulation or simultaneously with LPS stimulation. TNF-α concentration in the culture supernatant was detected using an enzyme-linked immunosorbent assay kit. Expression of NF-κB p65 subunit protein in cell nuclei was examined by Western blot. The expression of PCNA in cell nuclei was used as the control. Expressions of cellular p-IKKα/β, p-IκBα, p-p65, as well as IKKα/β, IκBα, p65 and GAPDH proteins were determined by Western blot. Of all, the expressions of IKKα/β, IκBα, p65, and GAPDH in cell were used as the controls. (a) TNF-α concentration in the culture supernatant of cells treated with 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 2 h applied simultaneously with LPS stimulation. (b) TNF-α concentration in the culture supernatant in cells treated with 100% oxygen or 0.5 MAC isoflurane in 60% oxygen for 2 h applied 1 h after LPS stimulation. (c) Expressions of cellular p-IKKα/β, p-IκBα, p-p65, as well as IKKα/β, IκBα, p65, and GAPDH proteins. Each represents three independent experiments. (d) Fluorescence images of the nuclear translocation of the NF-κB p65 subunit captured using a confocal laser scanning microscope. (e and f) Expression of NF-κB p65 subunit protein in cell nuclei. Data are expressed as the mean ± standard error (*n* = 6 in each group). \**P* \< 0.05 versus vehicle group; †*P* \< 0.05 versus LPS group. LPS: Lipopolysaccharide; MAC: Minimum alveolar concentration; NF-κB: Nuclear factor kappa B; PCNA: Proliferating cell nuclear antigen; p-IKKα/β: Phosphorylated IκB kinaseα/β; p-IκBα: Phosphorylated inhibitor of nuclear factor kappa Bα; p-p65: Phosphorylated p65 subunit of nuclear factor kappa B; IKKα/β: IκB kinaseα/β; IκBα: Inhibitor of nuclear factor kappa Bα; p65: p65 subunit of nuclear factor kappa B; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; TNF-α: Tumor necrosis factor-alpha; DAPI: 4',6-diamidino-2-phenylindole; ISO: Isoflurane; Oxy: Oxygen.](CMJ-130-840-g010){#F10}

The 0.5 minimum alveolar concentration isoflurane in 60% oxygen protected human peripheral blood mononuclear cells against *in vitro* sepsis induced by lipopolysaccharide or by plasma from septic patients {#sec2-21}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In LPS-stimulated human PBMCs, TNF-α (92.4 vs. 43.5 pg/ml, *P* \< 0.05) and IL-1β (55.7 vs. 25.0 pg/ml, *P* \< 0.05) concentrations in the cell culture supernatant were increased after the addition of LPS, which were inhibited significantly by 100% oxygen (TNF-α, 45.0 vs. 92.4 pg/ml. IL-1β, 14.7 vs. 55.7 pg/ml, all *P* \< 0.05) or 0.5 MAC isoflurane in 60% oxygen (TNF-α, 52.0 vs. 92.4 pg/ml. IL-1β, 16.6 vs. 55.7 pg/ml, all *P* \< 0.05) \[[Figure 11a](#F11){ref-type="fig"}\], and LPS stimulation also induced the nuclear translocation of NF-κB p65 subunit, which was blocked by 100% oxygen or 0.5 MAC isoflurane in 60% oxygen \[[Figure 11b](#F11){ref-type="fig"}\]. In human PBMCs stimulated by plasma from septic patients, plasma from septic patients also led to nuclear translocation of NF-κB p65 subunit, which was also blocked by 100% oxygen or 0.5 MAC isoflurane in 60% oxygen \[[Figure 11c](#F11){ref-type="fig"}\]. The above findings revealed that 0.5 MAC isoflurane in 60% oxygen reduces the inflammatory responses in human PBMCs by inhibiting nuclear translocation of NF-κBp65 subunit.

![The 0.5 minimum alveolar concentration isoflurane in 60% oxygen protected human peripheral blood mononuclear cells against *in vitro* sepsis induced by lipopolysaccharide or plasma from septic patients. An *in vitro* sepsis was induced in human PBMCs through incubation with 100 ng/ml LPS or by plasma from patients with sepsis. Cells were treated with 100% oxygen or 0.5 MAC isofluranein 60% oxygen for 2 h applied 1 h after the challenge with LPS or plasma. (a) IL-1β, IL-6, and TNF-α concentrations in the cell culture supernatant. Data are expressed as the mean ± standard error (*n* = 8 in each group). \**P* \< 0.05 versus vehicle group; †*P* \< 0.05 versus LPS group. (b and c) Fluorescence images of the nuclear translocation of the NF-κB p65 subunit were captured using a confocal laser scanning microscope in *in vitro* sepsis induced by lipopolysaccharide or plasma from septic patients, respectively (original magnification ×240). PBMC: Peripheral blood mononuclear cell; LPS: Lipopolysaccharide; MAC: Minimum alveolar concentration; IL-1β: Interleukin-1β; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-alpha; DAPI: 4',6-diamidino-2-phenylindole; ISO: Isoflurane; NF-κB: Nuclear factor kappa B; Oxy: Oxygen.](CMJ-130-840-g011){#F11}

D[iscussion]{.smallcaps} {#sec1-4}
========================

Sepsis is a complex pathology that arises from deregulated host inflammatory responses to systemic bacterial infection.\[[@ref1]\] To date, animal models of sepsis have been used as part of the development of novel therapeutic agents. In the present study, we found the 0.5 MAC isoflurane in 60% oxygen was the best combination of oxygen and isoflurane for reducing organ damage, especially lung injury and mortality resulting from sepsis caused by CLP, intraperitoneal injection of LPS, or zymosan. The 0.5 MAC isoflurane in 60% oxygen also significantly inhibited lung inflammation, peritonitis, and systemic inflammation to sepsis. The systemic inflammatory responses and the consequent multiple organ failure syndrome are the most severe manifestations of bacterial infections.\[[@ref30]\] CLP, which is a murine model of bacterial peritonitis, has been regarded as the "gold standard" animal model of sepsis.\[[@ref31][@ref32][@ref33][@ref34]\] Bacterial LPS is the major component of the outer membrane of Gram-negative bacteria which are considered one of the predominant causative organisms in sepsis; in experimental animals, LPS challenge leads to pathophysiological changes similar to the human septic shock syndrome.\[[@ref35]\] Zymosan, a substance derived from the cell wall of the yeast *Saccharomyces cerevisiae*, has been used as a tool to induce animal models with sterile sepsis/multiple organ dysfunction syndrome (MODS) in many studies.\[[@ref9][@ref13][@ref36]\] Several clinical trials have demonstrated a mortality ranging from 40% to 75% in patients with MODS arising from sepsis.\[[@ref37]\] In earlier studies, hyperoxia treatment was reported to preserve gut morphology and to improve gut barrier function, thus decreasing the amount of bacterial translocation.\[[@ref8][@ref9][@ref10]\] In addition, the beneficial effects of safe subtoxic regimens of normobaric hyperoxia were observed in various animal models of sepsis including gut-derived mouse sepsis,\[[@ref38]\] zymosan-induced mouse sterile sepsis,\[[@ref9]\] and early hyperdynamic porcine fecal peritonitis.\[[@ref10]\] However, prolonged exposure to hyperoxia leads to the generation of excessive ROS, which can cause acute inflammatory lung injury.\[[@ref20][@ref21][@ref22][@ref23]\] Some investigators observed that anesthetic dose isoflurane protects animals against septic shock.\[[@ref12][@ref39][@ref40]\] However, in sheep with LPS-induced sepsis, isoflurane anesthesia blunts cardiovascular compensatory mechanisms and aggravates lung and renal dysfunction in sepsis,\[[@ref15][@ref16][@ref17]\] which indicates that the use of anesthetic dose isoflurane in critically ill patients has serious adverse consequences on outcome. Recently, a number of trials have demonstrated the safety of long-time lower doses of isoflurane for ICU sedation.\[[@ref18][@ref19]\] The above statements supported the protective effects on sepsis by the 0.5 MAC isoflurane in 60% oxygen which would be a good therapy for sepsis with improved clinical safety and broader clinical applications. However, the mechanism regarding the interaction between oxygen and isoflurane remains to be further studied. The above results suggested that interaction existed in the protective effects on sepsis by oxygen and by isoflurane. The interaction between oxygen and isoflurane was also reported in a recent study.\[[@ref41]\] Blood monocytes and macrophages serve as the first line of host defense and are equipped to recognize and respond to infection by triggering an immune-inflammatory response in sepsis.\[[@ref42]\] The present study demonstrated that the 0.5 MAC isoflurane in 60% oxygen also protected RAW264.7 cells and human PBMCs against *in vitro* sepsis induced by LPS or plasma from septic patients. The NF-κB pathway is central to the regulation of inflammation. In sepsis, activation of NF-κB through its translocation to the nucleus leads to significant circulating levels of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.\[[@ref43][@ref44][@ref45]\] Moreover, the severity of sepsis is correlated with the elevation of HMGB1.\[[@ref46]\] Our results showed that LPS stimulation led to nuclear translocation of NF-κB p65 subunit in RAW264.7 macrophages and in human PBMCs, and plasma from septic patients also led to nuclear translocation of NF-κB p65 subunit in human PBMCs, which were blocked by 100% oxygen or 0.5 MAC isoflurane in 60% oxygen. We also found that LPS stimulation induced higher expressions of phospho-IKKβ/β, phospho-IκBβ, and phospho-p65 proteins in RAW264.7 macrophages, which were inhibited by treatment of 100% oxygen or 0.5 MAC isoflurane in 60% oxygen. According to the literature,\[[@ref47][@ref48][@ref49]\] the increased NF-κB activity and its polymorphism are associated with increased mortality in patients with sepsis, and the heightened expression of phospho-IκBβ is believed as an indicator of NF-κB activation in sepsis monocytes.\[[@ref42]\] Earlier studies reported that inhalation of 70% oxygen (48 h) fails to attenuate markers of lung inflammation, while intermittent 100% oxygen exerts favorable effects on markers of inflammation.\[[@ref50]\] Isoflurane anesthesia was also reported to have an inhibitory effect on renal inflammation and systemic inflammation both in murine septic peritonitis\[[@ref12][@ref39]\] and in rat endotoxemia.\[[@ref50]\] The above-mentioned findings demonstrated the important role of NF-κB inflammatory pathway in the sepsis protective effects of 0.5 MAC isoflurane in 60% oxygen, thus providing evidence for the safety of clinical application of combined administration of 0.5 MAC isoflurane with 60% oxygen.

In conclusion, combined administration of 0.5 MAC isoflurane with 60% oxygen is the optimal combination of oxygen and isoflurane for reducing lung injury and mortality of septic animals. This combination reduces inflammatory responses to sepsis in animals and human PMBCs, suggesting that combined therapy with a sedative dose isoflurane and 60% oxygen would be a novel, safer, and effective therapeutic measure for septic patients.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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